In 366 patients’ cases and the Cancer Cell Line Encyclopedia from Novartis and Broad Institute, which were analysed for mutations in CNR1, TRPV1 and PPARα, up to 3% were mutated (with no mutational hotspot) (Figure S2F,G). This evidence concerns the gene CNR1 and cancer.